Kyrollis Attalla

1.4k total citations
53 papers, 504 citations indexed

About

Kyrollis Attalla is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Kyrollis Attalla has authored 53 papers receiving a total of 504 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Surgery, 25 papers in Pulmonary and Respiratory Medicine and 11 papers in Oncology. Recurrent topics in Kyrollis Attalla's work include Bladder and Urothelial Cancer Treatments (33 papers), Renal cell carcinoma treatment (21 papers) and Urinary and Genital Oncology Studies (17 papers). Kyrollis Attalla is often cited by papers focused on Bladder and Urothelial Cancer Treatments (33 papers), Renal cell carcinoma treatment (21 papers) and Urinary and Genital Oncology Studies (17 papers). Kyrollis Attalla collaborates with scholars based in United States, Sweden and Australia. Kyrollis Attalla's co-authors include John P. Sfakianos, François Audenet, A. Ari Hakimi, Martin H. Voss, Manoj Monga, Shubha De, Stanley Weng, Reza Mehrazin, Ketan K. Badani and Robert J. Motzer and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer.

In The Last Decade

Kyrollis Attalla

46 papers receiving 501 citations

Peers

Countries citing papers authored by Kyrollis Attalla

Since Specialization

Citations

This map shows the geographic impact of Kyrollis Attalla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyrollis Attalla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyrollis Attalla more than expected).

Fields of papers citing papers by Kyrollis Attalla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyrollis Attalla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyrollis Attalla. The network helps show where Kyrollis Attalla may publish in the future.

Co-authorship network of co-authors of Kyrollis Attalla

This figure shows the co-authorship network connecting the top 25 collaborators of Kyrollis Attalla. A scholar is included among the top collaborators of Kyrollis Attalla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyrollis Attalla. Kyrollis Attalla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical utility of tumour‐informed circulating tumour DNA in patients with testicular cancer 2025 ·British Journal of Urology ·(unknown), (unknown), (unknown), Matthew D. Galsky, Che‐Kai Tsao, Kyrollis Attalla, Peter Wiklund, Reza Mehrazin, John P. Sfakianos	1
2	Efficacy of Bacillus Calmette-Guérin compared to sequential gemcitabine and docetaxel in Ta high-grade non-muscle invasive bladder cancer 2025 ·World Journal of Urology ·(unknown), (unknown), (unknown), (unknown), Nikhil Waingankar, Kyrollis Attalla, Peter Wiklund, Reza Mehrazin, John P. Sfakianos	0
3	Longitudinal Tumor-informed Circulating Tumor DNA Status Predicts Disease Upstaging and Poor Prognosis for Patients Undergoing Radical Cystectomy 2024 ·European Urology Oncology ·(unknown), (unknown), Shivaram Cumarasamy, (unknown), (unknown), (unknown), (unknown), Kyrollis Attalla, Reza Mehrazin, Peter Wiklund, John P. Sfakianos	17
4	Comparative Effectiveness of Bacillus Calmette-Guérin and Sequential Intravesical Gemcitabine and Docetaxel for Treatment-naïve Intermediate-risk Non–muscle-invasive Bladder Cancer 2024 ·European Urology Focus ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Kyrollis Attalla, Reza Mehrazin, Peter Wiklund, John P. Sfakianos	3
5	Undetectable pre‐radical cystectomy circulating tumour DNA status predicts improved oncological outcomes 2024 ·British Journal of Urology ·(unknown), (unknown), Jack Geduldig, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Kyrollis Attalla, Reza Mehrazin, Peter Wiklund, John P. Sfakianos	3
6	Tumor characteristics associated with detectable circulating tumor DNA preoperatively in patients with renal masses suspicious for RCC. 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), Matt D. Galsky, Kyrollis Attalla, John P. Sfakianos, Peter Wiklund, Nikhil Waingankar, Reza Mehrazin	0
7	Thromboembolic Events After Robotic Radical Cystectomy: A Comparative Analysis of Extended and Limited Prophylaxis 2024 ·Urology ·(unknown), Jack Geduldig, (unknown), (unknown), Reza Mehrazin, Kyrollis Attalla, Peter Wiklund, John P. Sfakianos	1
8	Outcomes from a prospectively implemented protocol using apixaban after robot‐assisted radical cystectomy 2023 ·British Journal of Urology ·(unknown), (unknown), Jack Geduldig, (unknown), Reza Mehrazin, Kyrollis Attalla, Peter Wiklund, John P. Sfakianos	8
9	Infections After Adoption of Antibiogram-directed Prophylaxis and Intracorporeal Urinary Diversion for Robot-assisted Radical Cystectomy 2023 ·European Urology Focus ·(unknown), (unknown), (unknown), (unknown), Daniel Ranti, John Pfail, (unknown), (unknown), (unknown), Gopi Patel, Sarah Schaefer, (unknown), Ketan K. Badani, (unknown), Reza Mehrazin, Kyrollis Attalla, Nikhil Waingankar, Peter Wiklund, John P. Sfakianos	1
10	Systemic Immunological Determinants of Oncological Outcomes After Surgery for Localized Renal Cell Carcinoma 2022 ·Clinical Genitourinary Cancer ·Andrew W. Silagy, Amy L. Tin, Phillip M. Rappold, Emily Vertosick, Roy Mano, Kyrollis Attalla, (unknown), Stanley Weng, Renzo G. DiNatale, Andrew J. Vickers, Daniel D. Sjoberg, Jonathan A. Coleman, Paul Russo, A. Ari Hakimi	1
11	A qualitative framework of non-selection factors for cytoreductive nephrectomy 2021 ·World Journal of Urology ·Andrew W. Silagy, Kyrollis Attalla, Renzo G. DiNatale, Kate Weiss, Stanley Weng, Roy Mano, (unknown), Julian Marcon, Ed Reznik, Ritesh R. Kotecha, Robert J. Motzer, Martin H. Voss, Jonathan Coleman, A. Ari Hakimi, Paul Russo	3
12	TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer 2020 ·Urologic Oncology Seminars and Original Investigations ·Kyrollis Attalla, Adam M. Farkas, Harry Anastos, François Audenet, Matthew D. Galsky, Nina Bhardwaj, John P. Sfakianos	12
13	Survival of Patients with Muscle-Invasive Urothelial Cancer of the Bladder with Residual Disease at Time of Cystectomy: A Comparative Survival Analysis of Treatment Modalities in the National Cancer Database 2020 ·Bladder Cancer ·John Pfail, François Audenet, Alberto Martini, (unknown), Ishan Paranjpe, Jorge Daza, Kyrollis Attalla, Nikhil Waingankar, Reza Mehrazin, Peter Wiklund, Matthew D. Galsky, John P. Sfakianos	9
14	A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response 2020 ·Nature Communications ·A. Ari Hakimi, Kyrollis Attalla, Renzo G. DiNatale, Irina Ostrovnaya, Jessica Flynn, Kyle A. Blum, Yasser Ged, Douglas R. Hoen, Sviatoslav M. Kendall, Ed Reznik, Anita S. Bowman, (unknown), Christopher J. Fong, Fengshen Kuo, Martin H. Voss, Timothy A. Chan, Robert J. Motzer	44
15	The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management 2020 ·European Urology ·Stanley Weng, Renzo G. DiNatale, Andrew W. Silagy, Roy Mano, Kyrollis Attalla, (unknown), Kate Weiss, Nicole Benfante, Andrew Winer, Jonathan Coleman, Victor E. Reuter, Paul Russo, Ed Reznik, Satish K. Tickoo, A. Ari Hakimi	33
16	The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy 2019 ·European Urology Oncology ·Renzo G. DiNatale, Wanling Xie, Maria F. Becerra, Andrew W. Silagy, Kyrollis Attalla, Alejandro Sánchez, Roy Mano, Julian Marcon, Kyle A. Blum, Nicole Benfante, Martin H. Voss, Robert J. Motzer, Jonathan Coleman, Toni K. Choueiri, Ed Reznik, Paul Russo, Daniel Y.C. Heng, A. Ari Hakimi	19
17	Current Role of Checkpoint Inhibitors in Urologic Cancers 2018 ·Cancer treatment and research ·Kyrollis Attalla, John P. Sfakianos, Matthew D. Galsky	5
18	The evolution of bladder cancer genomics: What have we learned and how can we use it? 2018 ·Urologic Oncology Seminars and Original Investigations ·François Audenet, Kyrollis Attalla, John P. Sfakianos	76
19	Squamous Cell Carcinoma of the Renal Pelvis: Atypical Presentation of a Rare Malignancy 2017 ·Urology Case Reports ·Kyrollis Attalla, Kenneth Haines, Daniel M. Labow, Reza Mehrazin	2
20	Demographic and socioeconomic predictors of treatment delays, pathologic stage, and survival among patients with penile cancer: A report from the National Cancer Database 2017 ·Urologic Oncology Seminars and Original Investigations ·Kyrollis Attalla, David J. Paulucci, Kyle A. Blum, Harry Anastos, Kelvin A. Moses, Ketan K. Badani, Philippe E. Spiess, John P. Sfakianos	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact